Delayed Nasdaq Stockholm 09:25:56 2024-04-25 am EDT 5-day change 1st Jan Change
0.936 SEK +4.93% Intraday chart for NEOS AB -0.43% -57.45%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Air Astana Partner with Italy-based Neos MT
NeoDynamics AB Announces Appointment of Matilda Salén as Its New Chief Executive Officer CI
Anna Eriksrud Announces Desire to Retire as CEO of NeoDynamics AB CI
NeoDynamics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
NeoDynamics AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NeoDynamics AB Announces CFO Aaron Wong to Leave by End of May 2024 CI
Neodynamics Launches Device Registry in Germany, Cost-Effective Collection of Real-World Data CI
NeoDynamics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
NeoDynamics Announces Cost Reduction Plan CI
NeoDynamics AB Receives New Order from Western Rhineland-Palatinate Hospital in Germany CI
NeoDynamics Soars 42% Amid First US Order for Invasive Biopsy System NeoNavia MT
NeoDynamics AB Receives First Commercial Order from Top University Hospital CI
NeoDynamics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Neodynamics AB Presents Results of Pulse Study At the Annual Congress of the German Society of Senology, Munich CI
NeoDynamics Plans SEK72 Million Rights Issue to Fund Commercialization, Marketing Operations MT
NeoDynamics AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
NeoDynamics AB Presents Final Data Set from NeoDynamics' Pulse Study Presented at the SBI Breast Imaging Symposium CI
Sweden’s NeoDynamics Launches New Biopsy Technology in US MT
Neodynamics, Inc. Announces U.S. Availability of Neonavia, the First and Only Pulse Biopsy Technology, Fda-Cleared in Breast and Axillary Lymph Node Biopsies CI
Neodynamics AB Announces Delivery of Corepulse Needles to 23 Hospitals CI
NeoDynamics Receives Chinese Patent for NeoNavia FlexiPulse MT
NeoDynamics AB Receives Chinese Patent for FlexiPulse Needle Design CI
NeoDynamics AB announced that it expects to receive SEK 14 million in funding from Gryningskust Holding AB CI
NeoDynamics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
NeoDynamics Announces Changes to Board of Directors CI
Chart NEOS AB
More charts
NeoDynamics AB (publ) is a Sweden-based company engaged in the medical industry. The Company focuses on developing and commercializing products for breast cancer screening, imaging, and breast cancer treatments. The Company’s product NeoNavia, enables a pulse biopsy system for ultrasound guided tissue sampling. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour whilst enabling tissue samples from both breasts and lymph nodes. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at clinics in United Kingdom, Germany, and Sweden.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. NEOD Stock
  4. News NEOS AB
  5. Neodynamics Teams Up With Uniphar for Biopsy System Launch in US